# Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

> **NCT07371923** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Zanubrutinib+Pola-R-CHP

## Key facts

- **NCT ID:** NCT07371923
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371923, "Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07371923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*